Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Science · 2024
DOI: 10.1126/science.adh4567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Krishnan K Mahadevan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Dendritic Cells, Immunotherapy, Pancreatic Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis (ptPDAC), antigen-presenting type I conventional dendritic cells (cDC1s) are specifically activated. Immune checkpoint blockade therapy (iCBT) leads to cytotoxic CD8 + T cell activation and elimination of ptPDAC with restoration of life span even upon PDAC rechallenge. Using PDAC antigen-loaded cDC1s as a vaccine, immunotherapy-resistant PDAC was rendered sensitive to iCBT with elimination of tumors. cDC1 vaccination coupled with iCBT identified specific CDR3 sequences in the tumor-infiltrating CD8 + T cells with potential therapeutic importance. This study identifies a fundamental difference in the immune microenvironment in PDAC concurrent with, or without, pancreatitis and provides a rationale for combining cDC1 vaccination with iCBT as a potential treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Bioengineering, Rice University, Houston, TX, USA.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Krishnan K Mahadevan, Allison M Dyevoich, Yang Chen, Bingrui Li, Amari M Sockwell, Kathleen M McAndrews, Lakshmi Kavitha Sthanam, Huamin Wang, Shabnam Shalapour, Stephanie S Watowich, Raghu Kalluri
Förderung
- NIAID NIH HHS
- NCI NIH HHS
Zitieren
APA
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., Watowich, S. S., & Kalluri, R. (2024). Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. https://doi.org/10.1126/science.adh4567
Vancouver
Mahadevan KK, Dyevoich AM, Chen Y, Li B, Sugimoto H, Sockwell AM, et al. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 2024. doi:10.1126/science.adh4567
BibTeX
@article{Mahadevan2024,
author = {Mahadevan, Krishnan K and Dyevoich, Allison M and Chen, Yang and Li, Bingrui and Sugimoto, Hikaru and Sockwell, Amari M and McAndrews, Kathleen M and Sthanam, Lakshmi Kavitha and Wang, Huamin and Shalapour, Shabnam and Watowich, Stephanie S and Kalluri, Raghu},
title = {Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer},
journal = {Science},
year = {2024},
doi = {10.1126/science.adh4567}
}
EUVIMED